<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>secondquartercover.txt
<TEXT>


               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C. 20549


                            FORM 8K

       Current Report Pursuant to Section 13 or 15(d) of
              The Securities Exchange Act of 1934



  Date of Report (Date of earliest event reported): July 15, 2003


                        JOHNSON & JOHNSON

     (Exact name of registrant as specified in its charter)


    New Jersey                1-3215              22-1024240

(State or other             Commission        (I.R.S. Employer
jurisdiction                File Number)      Identification No.)
of incorporation)



 One Johnson & Johnson Plaza, New Brunswick, New Jersey   08933

           (Address of principal executive offices)    (zip code)


Registrant's telephone number including area code: (732) 524-0400


Item 5.   Other Events.

On July 15, 2003, Johnson & Johnson ("J&J") issued the attached
press release announcing its sales and earnings for the period
ended June 29, 2003.

Item 9.

On July 15, 2003, Johnson & Johnson announced its consolidated
financial results for the second quarter ended June 29, 2003.
A copy of this press release is furnished with this report as an
exhibit to Form 8-K.  The information contained in this report
on Form 8-K is being furnished pursuant to Item 12 under Item 9 of
Form 8-K as directed by the U.S. Securities and Exchange
Commission in Release No. 34-47583.

The following non-GAAP disclosures were included in the press release
to provide investors with information regarding the underlying business.

Sales growth excluding currency is presented, as the Company believes
that it is a meaningful measure of comparative performance.  Currency
fluctuations that are not within the control of management can have
significant impact on the comparability of reported sales and could
disguise meaningful trends in the business.

The Company provided earnings before provision for taxes on income, net
earnings and earnings per share (diluted) excluding in-process research
and development (IPR&D) charges as these charges are related to business
combination transactions.  The Company believes that presenting
information that excludes IPR&D related amounts is helpful in evaluating
the on-going business operations.

The press release dated July 15, 2003 was revised to reflect that the U.S.
Food and Drug Administration approval for LEVAQUIN was for use in the
treatment of chronic bacterial prostatitis and not chronic acute bacterial
prostatitis.  Additionally, the currency percentages have been added to all
references to sales growth rates in the text of the press release.



(c)  Exhibits

Exhibit No.       Description of Exhibit

99.15     Press Release dated July 15, 2003 (revised July 18, 2003)
          for the period ended June 29, 2003.

99.2O     Unaudited Comparative Supplementary Sales Data and
          Condensed Consolidated Statement of Earnings for the
          second quarter and 6 months year-to-date.




                            SIGNATURE



Pursuant to the requirements of the Securities Exchange Act of
1934,  the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.



                                   JOHNSON & JOHNSON




Date: July 18, 2003           By: /s/ Stephen J. Cosgrove
                              Stephen J. Cosgrove
                              Chief Accounting Officer




</TEXT>
</DOCUMENT>